 |
|
ramucirumab
A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonym: | | anti-VEGFR-2 fully human monoclonal antibody IMC-1121B | | | | Code name: | | IMC-1121B | | | | Chemical structure names: | | - immunoglobulin G1, anti-(human vascular endothelial growth factor receptor type VEGFR-2 extracellular domain) (human monoclonal IMC-1121B γ-chain), disulfide with human monoclonal IMC-1121B κ-chain, dimer
- immunoglobulin G1, anti-(vascular endothelial growth factor receptor 2 (EC 2.7.10.1 or protein-tyrosine kinase receptor Flk-1 or CD309 antigen) extracellular domain); human monoclonal IMC-1121B γ1 heavy chain (219-214')-disulfide with human monoclonal IMC-1121B κ light chain (225-225'':228-228'')-bisdisulfide dimer
| | |
|
|
